… dosing schedules to delay resistance [14, 15]. We used these methods to evaluate … dosing
schedules of erlotinib and identified twice weekly high dose plus daily low-dose erlotinib as …

… and erlotinib in patients with advanced PDAC. Study patients received Gem at the dose of
… PD) or unacceptable toxicity; erlotinib was administered as a daily oral dose of 100 mg from …

… managed adequately with these treatments, erlotinib dose can be momentarily reduced in
50-… is severe (grade ≥3), treatment may be suspended and then reinitiated at a reduced dose. …

… study was that by increasing the dose of erlotinib until the development of a … erlotinib in the
first-line setting of advanced NSCLC evaluated prospectively if increasing the dose of erlotinib …

… thereby reducing the dose of erlotinib for patients in PFS, the model used the average erlotinib
dose of 91.13 mg/d. Costs of supportive care were taken from a previous study. Published …

… mg of erlotinib as the recommended dose and schedule for each of these agents. In the case
of gefitinib, a dose of 250 mg is less toxic and as effective as a dose of … dose. In the case of …

… a much higher rate of dose reduction and discontinuation than was erlotinib (… dose reduction
(n=3) and the only serious adverse event related to treatment (n=2) in patients on erlotinib…

… Drug costs accounted for wastage; however, the cost impact of dose reductions and dose
delays was not addressed. Further, it was expected that treatment costs would be incurred …

… dose could not be administered in this study because of sequential erlotinib on days 15 to 28;
however, the doses … Patients in the GC-placebo arm attained a response rate of 24.4% and …

… ,12 suggesting that dose reduction might particularly impair … whether treatment with
reduced-dose erlotinib (≤100 mg daily… -dose erlotinib has similar efficacy to the MTD of erlotinib …